We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Doric Nimrod Air One Limited | LSE:DNA | London | Ordinary Share | GG00B4MF3899 | ORD PRF SHS NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 60.00 | 59.00 | 61.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
The Food and Drug Administration said it's "unclear" whether positive responses seen in clinical trials involving Genentech Inc.'s (DNA) Avastin are sufficient to support accelerated approval of the drug to treat an aggressive type of brain cancer.
Genentech is seeking FDA approval to market Avastin, already approved to treat advanced breast, lung and colorectal cancer, for patients who suffer from an aggressive form of brain cancer in which the survival rate is 9 months to 12 months.
A panel of outside medical experts will discuss Avastin at an FDA sponsored meeting Tuesday. The panel will decide whether to recommend approval to expand the drug to treat brain cancer. The FDA generally follows the group's advice.
The FDA said it's "unclear weather the response rate and duration of response seen" in Genentech's application are sufficient, according to briefing documents posted on the agency's Web site.
-By Jared A. Favole, Dow Jones Newswires; 202.862.9207; jared.favole@dowjones.com
1 Year Doric Nimrod Air One Chart |
1 Month Doric Nimrod Air One Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
